Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. (Q40370932)

19 September 2017

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. (English)

1 reference

19 September 2017

M Neuenhahn

1

1 reference

19 September 2017

J Albrecht

2

1 reference

19 September 2017

M Odendahl

3

1 reference

19 September 2017

F Schlott

4

1 reference

19 September 2017

G Dössinger

5

1 reference

19 September 2017

M Schiemann

6

1 reference

19 September 2017

S Lakshmipathi

7

1 reference

19 September 2017

K Martin

8

1 reference

19 September 2017

D Bunjes

9

1 reference

19 September 2017

S Harsdorf

10

1 reference

19 September 2017

E M Weissinger

11

1 reference

19 September 2017

H Menzel

12

1 reference

19 September 2017

M Verbeek

13

1 reference

19 September 2017

L Uharek

14

1 reference

19 September 2017

N Kröger

15

1 reference

19 September 2017

E Wagner

16

1 reference

19 September 2017

G Kobbe

17

1 reference

19 September 2017

T Schroeder

18

1 reference

19 September 2017

M Schmitt

19

1 reference

19 September 2017

G Held

20

1 reference

19 September 2017

W Herr

21

1 reference

19 September 2017

L Germeroth

22

1 reference

19 September 2017

H Bonig

23

1 reference

19 September 2017

T Tonn

24

1 reference

19 September 2017

H Einsele

25

1 reference

19 September 2017

D H Busch

26

1 reference

19 September 2017

G U Grigoleit

27

1 reference

19 September 2017

16 January 2017

1 reference

19 September 2017

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2017.16

19 September 2017

0 references

cites work

Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Clinical-scale isolation of 'minimally manipulated' cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Disparate individual fates compose robust CD8+ T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Big bang theory of stem-like T cells confirmed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Rapid salvage treatment with virus-specific T cells for therapy-resistant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

MHC multimer-guided and cell culture-independent isolation of functional T cell receptors from single cells facilitates TCR identification for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Cytomegalovirus: pathogen, paradigm, and puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Novel serial positive enrichment technology enables clinical multiparameter cell sorting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

7 January 2021

inferred from DOI database lookup

Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

7 January 2021

inferred from DOI database lookup

Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.16

7 January 2021

inferred from DOI database lookup

Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28090089

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/LEU.2017.16

1 reference

Dimensions Publication ID

19 September 2017

0 references

1 reference